Trial Profile
A study evaluating safety and efficacy of 8-weeks Ledipasvir/Sofosbuvir combination in chronic Hepatitis C genotype 4–infected patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2017
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 15 Nov 2017 New trial record
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases